Pharmacosmos A/S
🇩🇰Denmark
Clinical Trials
80
Active:44
Completed:28
Trial Phases
4 Phases
Phase 1:22
Phase 2:3
Phase 3:21
+1 more phases
Drug Approvals
5
NMPA:5
Drug Approvals
Ferric Derisomaltose Injection
- Product Name
- 异麦芽糖酐铁注射液
- Approval Number
- 国药准字HJ20210006
- Approval Date
- Jan 30, 2021
NMPA
Ferric Derisomaltose Injection
- Product Name
- 异麦芽糖酐铁注射液
- Approval Number
- 国药准字HJ20210005
- Approval Date
- Jan 30, 2021
NMPA
Ferric Derisomaltose Injection
- Product Name
- 异麦芽糖酐铁注射液
- Approval Number
- 国药准字HJ20210007
- Approval Date
- Jan 30, 2021
NMPA
Clinical Trials
Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials
Phase 1
22 (44.9%)Phase 3
21 (42.9%)Phase 2
3 (6.1%)Phase 4
3 (6.1%)Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
Phase 3
Not yet recruiting
- Conditions
- Chronic Heart FailureIron Deficiencies
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 1900
- Registration Number
- NCT06929806
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 90
- Registration Number
- NCT05693909
- Locations
- 🇩🇰
Pharmacosmos Investigational Site, Copenhagen, Denmark
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Phase 4
Not yet recruiting
- Conditions
- Malignant LymphomaMultiple Myeloma
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 150
- Registration Number
- NCT05545202
Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
Phase 3
Recruiting
- Conditions
- Iron Deficiency, Anaemia in Children
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 200
- Registration Number
- NCT05179226
- Locations
- 🇺🇸
Pharmacosmos Investigational Site, Miami, Florida, United States
A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 97
- Registration Number
- NCT03466983
- Locations
- 🇩🇰
Pharmacosmos Investigational Site, Silkeborg, Denmark
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found